respond to other treatments. The injection, known as amivantamab, shrank the tumors of more than a third of patients, with dramatic changes seen WITHIN WEEKS. In 15 of them, researchers found amivantamab had melted away their tumors altogether.
August 24, 2026 at 5:25 PM
respond to other treatments. The injection, known as amivantamab, shrank the tumors of more than a third of patients, with dramatic changes seen WITHIN WEEKS. In 15 of them, researchers found amivantamab had melted away their tumors altogether.
Amivantamab is a targeted bispecific antibody and works by targeting cancer in three ways. It blocks both EGFR (epidermal growth factor receptor), a protein that helps tumors grow, and MET, a pathway that cancer cells often use to escape treatment. It also helps activate the immune system to attack
August 24, 2026 at 5:26 PM
Amivantamab is a targeted bispecific antibody and works by targeting cancer in three ways. It blocks both EGFR (epidermal growth factor receptor), a protein that helps tumors grow, and MET, a pathway that cancer cells often use to escape treatment. It also helps activate the immune system to attack
Amivantamab is now being evaluated in about 60 clinical trials, primarily for lung cancer, but also for colorectal, brain and gastric cancers.
August 3, 2026 at 4:14 PM
Amivantamab is now being evaluated in about 60 clinical trials, primarily for lung cancer, but also for colorectal, brain and gastric cancers.
Amivantamab is now being evaluated in about 60 clinical trials, primarily for lung cancer, but also for colorectal, brain and gastric cancers.
August 24, 2026 at 5:32 PM
Amivantamab is now being evaluated in about 60 clinical trials, primarily for lung cancer, but also for colorectal, brain and gastric cancers.
injection, for adult patients with the same conditions where amivantamab is already approved to be given through a vein, or intravenously (IV).
August 24, 2026 at 5:27 PM
injection, for adult patients with the same conditions where amivantamab is already approved to be given through a vein, or intravenously (IV).
Patients receiving amivantamab lived for a median of 12.5 months overall after starting treatment, despite having a form of cancer with very poor outcomes, once standard treatments stop working.
August 24, 2026 at 5:32 PM
Patients receiving amivantamab lived for a median of 12.5 months overall after starting treatment, despite having a form of cancer with very poor outcomes, once standard treatments stop working.
Smart jab can shrink head & neck cancer tumours within 6 weeks, trial finds.
Triple-action therapy drug amivantamab could be given as an injection to help treat recurrent or metastatic cancers.
🧪💉 #medsky
www.theguardian.com/science/2025...
Triple-action therapy drug amivantamab could be given as an injection to help treat recurrent or metastatic cancers.
🧪💉 #medsky
www.theguardian.com/science/2025...
Smart jab can shrink head and neck cancer tumours within six weeks, trial finds
Triple-action therapy drug amivantamab could be given as an injection to help treat recurrent or metastatic cancers
www.theguardian.com
October 20, 2025 at 6:25 AM
Smart jab can shrink head & neck cancer tumours within 6 weeks, trial finds.
Triple-action therapy drug amivantamab could be given as an injection to help treat recurrent or metastatic cancers.
🧪💉 #medsky
www.theguardian.com/science/2025...
Triple-action therapy drug amivantamab could be given as an injection to help treat recurrent or metastatic cancers.
🧪💉 #medsky
www.theguardian.com/science/2025...
Doctors have hailed “unprecedented” trial results that show a triple-action cancer jab can eradicate entire tumors in patients with head and neck cancer.
The jab, called amivantamab, shrank the tumors of more than a third of patients.
www.theguardian.com/science/2026...
The jab, called amivantamab, shrank the tumors of more than a third of patients.
www.theguardian.com/science/2026...
Cancer jab can eradicate entire tumours in patients, trial shows
Jab brought ‘unprecedentedly strong responses’ in patients whose disease had become resistant to chemotherapy and immunotherapy
www.theguardian.com
May 31, 2026 at 7:28 AM
Doctors have hailed “unprecedented” trial results that show a triple-action cancer jab can eradicate entire tumors in patients with head and neck cancer.
The jab, called amivantamab, shrank the tumors of more than a third of patients.
www.theguardian.com/science/2026...
The jab, called amivantamab, shrank the tumors of more than a third of patients.
www.theguardian.com/science/2026...
Patients receiving amivantamab lived for a median of 12.5 months overall after starting treatment, despite having a form of cancer with very poor outcomes, once standard treatments stop working.
August 3, 2026 at 4:13 PM
Patients receiving amivantamab lived for a median of 12.5 months overall after starting treatment, despite having a form of cancer with very poor outcomes, once standard treatments stop working.
Researchers said the injection had also shown similar results in patients with lung cancer. Unlike many cancer treatments, amivantamab is given as a tiny injection under the skin rather than via an intravenous drip, making treatment quicker and more convenient for patients and much easier to
August 24, 2026 at 5:30 PM
Researchers said the injection had also shown similar results in patients with lung cancer. Unlike many cancer treatments, amivantamab is given as a tiny injection under the skin rather than via an intravenous drip, making treatment quicker and more convenient for patients and much easier to
Early Phase 1b/2 results for amivantamab in advanced head & neck cancer are noteworthy. For 102 patients who'd exhausted other options, 15 had tumors eliminated & 28 saw them shrink. This kind of progress against such aggressive cancer deserves recognition.
Unprecedented results of new cancer therapy demonstrate significant progress in head and neck cancer
A novel triple-action cancer drug, amivantamab, has shown promising results in a Phase 1b/2 clinical trial for patients with HPV-unrelated recurrent/metastatic head and neck squamous cell cancer who h
adanews.ada.org
September 21, 2026 at 2:02 PM
Early Phase 1b/2 results for amivantamab in advanced head & neck cancer are noteworthy. For 102 patients who'd exhausted other options, 15 had tumors eliminated & 28 saw them shrink. This kind of progress against such aggressive cancer deserves recognition.
the tumor. What some may not know is that Amivantamab (brand name Rybrevant) used to treat certain types of advanced or metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations, was approved last December by the FDA to be given under the skin, which is called a subcutaneous (SQ)
August 24, 2026 at 5:27 PM
the tumor. What some may not know is that Amivantamab (brand name Rybrevant) used to treat certain types of advanced or metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations, was approved last December by the FDA to be given under the skin, which is called a subcutaneous (SQ)
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC | NEJM
Amivantamab plus lazertinib (amivantamab–lazertinib) has shown clinically meaningful
and durable antitumor activity in patients with previously untreated or osimertinib-pretreated
EGFR (epidermal g...
www.nejm.org
October 24, 2024 at 9:17 PM
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
Phenomenal results being reported for a clinical trial for injections of the drug Amivantamab for people with advanced / metastatic head and neck cancers resistant to chemotherapy and immunotherapy. From a personal perspective this brings me great hope #cansky
www.theguardian.com/science/2026...
www.theguardian.com/science/2026...
Cancer jab can eradicate entire tumours in patients, trial shows
Jab brought ‘unprecedentedly strong responses’ in patients whose disease had become resistant to chemotherapy and immunotherapy
www.theguardian.com
May 31, 2026 at 10:45 AM
Phenomenal results being reported for a clinical trial for injections of the drug Amivantamab for people with advanced / metastatic head and neck cancers resistant to chemotherapy and immunotherapy. From a personal perspective this brings me great hope #cansky
www.theguardian.com/science/2026...
www.theguardian.com/science/2026...
First-Line Amivantamab Plus Lazertinib Wins EU Approval for EGFR+ Advanced NSCLC #lcsm #oncology www.onclive.com/view/first-l...
First-Line Amivantamab Plus Lazertinib Wins EU Approval for EGFR+ Advanced NSCLC
The European Commission approved first-line amivantamab plus lazertinib for EGFR-mutated advanced non–small cell lung cancer.
www.onclive.com
January 21, 2025 at 4:12 PM
First-Line Amivantamab Plus Lazertinib Wins EU Approval for EGFR+ Advanced NSCLC #lcsm #oncology www.onclive.com/view/first-l...
1/8 🩺 NEW JAB ERADICATES CANCER TUMOURS 🩺
Amivantamab shrank tumours in >30% of cases within weeks.
In 15 patients, it melted them away entirely.
Source: The Guardian
#MedSky #PublicHealth #Oncology #CancerJab #Amivantamab
Amivantamab shrank tumours in >30% of cases within weeks.
In 15 patients, it melted them away entirely.
Source: The Guardian
#MedSky #PublicHealth #Oncology #CancerJab #Amivantamab
May 30, 2026 at 7:13 PM
1/8 🩺 NEW JAB ERADICATES CANCER TUMOURS 🩺
Amivantamab shrank tumours in >30% of cases within weeks.
In 15 patients, it melted them away entirely.
Source: The Guardian
#MedSky #PublicHealth #Oncology #CancerJab #Amivantamab
Amivantamab shrank tumours in >30% of cases within weeks.
In 15 patients, it melted them away entirely.
Source: The Guardian
#MedSky #PublicHealth #Oncology #CancerJab #Amivantamab
🧪 Excellent explainer thread on the initial findings (just shared at the ASCO conference) on a possibly amazing new treatment for head and neck cancers.
Now in clinical trials, amivantamab works both by blocking a growth factor in tumor cells and also by directing an immune response against them.
Now in clinical trials, amivantamab works both by blocking a growth factor in tumor cells and also by directing an immune response against them.
June 12, 2026 at 12:16 AM
🧪 Excellent explainer thread on the initial findings (just shared at the ASCO conference) on a possibly amazing new treatment for head and neck cancers.
Now in clinical trials, amivantamab works both by blocking a growth factor in tumor cells and also by directing an immune response against them.
Now in clinical trials, amivantamab works both by blocking a growth factor in tumor cells and also by directing an immune response against them.
2024 approvals: Summary of 14 new drugs/indications in #LungCancer by FDA
1. #Tepotinib
2. #Osimertinib x2
3. #Alectinib
4. #Tarlatamab
5. #Zenocutuzumab
6. #Durvalumab x2
7. #Amivantamab x2
8. #Nivolumab (now SubQ)
9. #Ensartinib
#lcsm #OncSky #MedSky #Cancer
1. #Tepotinib
2. #Osimertinib x2
3. #Alectinib
4. #Tarlatamab
5. #Zenocutuzumab
6. #Durvalumab x2
7. #Amivantamab x2
8. #Nivolumab (now SubQ)
9. #Ensartinib
#lcsm #OncSky #MedSky #Cancer
December 28, 2024 at 4:09 PM
2024 approvals: Summary of 14 new drugs/indications in #LungCancer by FDA
1. #Tepotinib
2. #Osimertinib x2
3. #Alectinib
4. #Tarlatamab
5. #Zenocutuzumab
6. #Durvalumab x2
7. #Amivantamab x2
8. #Nivolumab (now SubQ)
9. #Ensartinib
#lcsm #OncSky #MedSky #Cancer
1. #Tepotinib
2. #Osimertinib x2
3. #Alectinib
4. #Tarlatamab
5. #Zenocutuzumab
6. #Durvalumab x2
7. #Amivantamab x2
8. #Nivolumab (now SubQ)
9. #Ensartinib
#lcsm #OncSky #MedSky #Cancer
As a Stage 4 head and neck cancer patient myself, the results of this trial are outstanding... "Early results show 76% of this group saw their tumours shrink or stop growing" #cansky 🧪
www.theguardian.com/science/2025...
www.theguardian.com/science/2025...
Smart jab can shrink head and neck cancer tumours within six weeks, trial finds
Triple-action therapy drug amivantamab could be given as an injection to help treat recurrent or metastatic cancers
www.theguardian.com
October 19, 2025 at 3:53 PM
As a Stage 4 head and neck cancer patient myself, the results of this trial are outstanding... "Early results show 76% of this group saw their tumours shrink or stop growing" #cansky 🧪
www.theguardian.com/science/2025...
www.theguardian.com/science/2025...
FDA Approves Subcutaneous Amivantamab for Faster, Safer Treatment - Stephen V Liu
@stephenvliu.bsky.social
oncodaily.com/voices/steph...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
@stephenvliu.bsky.social
oncodaily.com/voices/steph...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
Stephen V Liu: FDA Approves Subcutaneous Amivantamab for Faster, Safer Treatment - OncoDaily
Stephen V Liu: FDA Approves Subcutaneous Amivantamab for Faster, Safer Treatment / Stephen V Liu
oncodaily.com
December 18, 2025 at 3:56 PM
FDA Approves Subcutaneous Amivantamab for Faster, Safer Treatment - Stephen V Liu
@stephenvliu.bsky.social
oncodaily.com/voices/steph...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
@stephenvliu.bsky.social
oncodaily.com/voices/steph...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
ESMO GI 2025 Highlights: OrigAMI-1 Trial on Amivantamab Rechallenge in mCRC
@myesmo.bsky.social
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO #ESMOGI25 #OrigAMI1 #Amivantamab #mCRC #GIOnc
@myesmo.bsky.social
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO #ESMOGI25 #OrigAMI1 #Amivantamab #mCRC #GIOnc
OrigAMI-1 Trial at ESMO GI 2025: Amivantamab in mCRC
The OrigAMI-1 trial explored the efficacy of amivantamab monotherapy in left-sided RAS/BRAF wild-type metastatic colorectal cancer (mCRC).
oncodaily.com
July 3, 2025 at 10:04 PM
ESMO GI 2025 Highlights: OrigAMI-1 Trial on Amivantamab Rechallenge in mCRC
@myesmo.bsky.social
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO #ESMOGI25 #OrigAMI1 #Amivantamab #mCRC #GIOnc
@myesmo.bsky.social
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO #ESMOGI25 #OrigAMI1 #Amivantamab #mCRC #GIOnc
“The injection, known as amivantamab, shrank the tumors of more than a third of patients, with dramatic changes seen WITHIN WEEKS. In 15 of them, researchers found amivantamab had melted away their tumors altogether.” 🤯🤯🤯👏👏👏
Links in 🧵👇
Links in 🧵👇
August 4, 2026 at 2:33 PM
“The injection, known as amivantamab, shrank the tumors of more than a third of patients, with dramatic changes seen WITHIN WEEKS. In 15 of them, researchers found amivantamab had melted away their tumors altogether.” 🤯🤯🤯👏👏👏
Links in 🧵👇
Links in 🧵👇
Press release: MARIPOSA regimen of first-line amivantamab plus lazertinib shows a significant improvement in overall survival over osimertinib alone in #EGFR NSCLC. Full data to be presented but improvement in median OS expected to be over 12 months.
www.jnj.com/media-center...
www.jnj.com/media-center...
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) shows statistically significant and clinically meaningful improvement in overall survival versus osimertinib
Median overall survival improvement expected to exceed one year First and only regimen with a survival benefit over current standard of care in first-line treatment of EGFR-mutated lung cancer
www.jnj.com
January 7, 2025 at 1:34 PM
Press release: MARIPOSA regimen of first-line amivantamab plus lazertinib shows a significant improvement in overall survival over osimertinib alone in #EGFR NSCLC. Full data to be presented but improvement in median OS expected to be over 12 months.
www.jnj.com/media-center...
www.jnj.com/media-center...
MARIPOSA phase 3 trial: In advanced non–small-cell lung cancer with EGFR mutations, amivantamab–lazertinib led to longer overall survival than osimertinib but was associated with an increased risk of adverse events of grade 3 or higher. nej.md/4p6j53k
#WCLC25 | @iaslc.bsky.social
#WCLC25 | @iaslc.bsky.social
September 7, 2025 at 6:52 AM
MARIPOSA phase 3 trial: In advanced non–small-cell lung cancer with EGFR mutations, amivantamab–lazertinib led to longer overall survival than osimertinib but was associated with an increased risk of adverse events of grade 3 or higher. nej.md/4p6j53k
#WCLC25 | @iaslc.bsky.social
#WCLC25 | @iaslc.bsky.social
The amivantamab injection successfully eradicated advanced head and neck tumors, providing an effective, rapid, and low-side-effect alternative for patients who had exhausted traditional treatment options.
Source: The Guardian/Cancer jab can eradicate entire tumours in patients, trial shows
Source: The Guardian/Cancer jab can eradicate entire tumours in patients, trial shows
August 1, 2026 at 12:00 AM
The amivantamab injection successfully eradicated advanced head and neck tumors, providing an effective, rapid, and low-side-effect alternative for patients who had exhausted traditional treatment options.
Source: The Guardian/Cancer jab can eradicate entire tumours in patients, trial shows
Source: The Guardian/Cancer jab can eradicate entire tumours in patients, trial shows